Skip to content

Evaluate the safety and efficacy of Nuxiwell injectable gel

Evaluate the safety and efficacy of Nuxiwell injectable gel for corection and restoration of mid-face volume

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190210042676N45
Enrollment
20
Registered
2025-07-21
Start date
2025-08-23
Completion date
Unknown
Last updated
2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Volume deficit of middle face area. Changes in skin texture

Interventions

Intervention group: A treatment session with a maximum of 2 to 4 ml of Nuxiwell brand injectable gel made by Amitis Nik Darou Company.In the Zygomaticomalar area and, if the physician's discretion, in

Sponsors

Amitis Nik Darou Company
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 65 Years

Inclusion criteria

Inclusion criteria: Men and women with 30 to 65 years old Moderate to very severe degree of volume reduction of middle face area, based on MFVDS(Allergan midface volume deficit scale) criteria Signing an informed consent form and agreed to follow up.

Exclusion criteria

Exclusion criteria: History of type 1 allergic reactions or anaphylaxis reaction Allergy or sensitivity to Ingredients of filler, lidocaine and proteins of microorganism producing HA (streptococcus) History of surgery or trauma in the injection area during the last six months Pregnant or lactating or planning to become pregnant in the near future while studying Use of antiplatelet drugs during 72 hours before treatment and anticoagulant drugs during 2 weeks before or during treatment.

Design outcomes

Primary

MeasureTime frame
Percentage of subjects with improvement in midface volume deficit scale. Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: Allergan midface volume deficit scale (MFVDS).

Secondary

MeasureTime frame
Percentage of subjects with improvement in midface volume deficit scale. Timepoint: Before intervention,12 and 24 weeks after intervention. Method of measurement: Allergan midface volume deficit scale (MFVDS).;Depth, area and volume of nasolabial fold. Timepoint: Before intervention and right after intervention and 4, 12 and 24 weeks later. Method of measurement: Visioface camera.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAniseh Samadi

Tehran University of Medical Sciences

aniseh_samadi@yahoo.com+98 21 8897 7921

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026